Abstracts tagged "Lymphocytes and methotrexate (MTX)"

Abstract Number: 2424 • 2017 ACR/ARHP Annual Meeting
CD8-Positive Lymphocytes in Biopsy Specimens Predict Spontaneous Regression of Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis Treated with Methotrexate
Tomohiro Kameda¹, Hiroaki Dobashi¹, Masayuki Inoo², Ikuko Onishi², Noriyuki Kurata², Mikiya Kato¹, Atsushi Kondo¹, Risa Wakiya¹, Hiromi Shimada¹, Shusaku Nakashima¹, Miharu Izumikawa¹ and Norimitsu Kadowaki¹, ¹Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan, ²Utazu hospital, Kagawa, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of developing lymphoproliferative disorders (LPDs). LPDs that develop in patients treated with methotrexate (MTX) are…
Abstract Number: 2724 • 2015 ACR/ARHP Annual Meeting
Methotrexate Treatment Could Modulate the Abnormal CD4+T Lymphocyte Subset Distribution in NaÏve Rheumatoid Arthritis Patients
Cristina Bohórquez Heras¹, Lucía Ruiz Gutiérrez¹, Carolina Garcia Torrijos², Ana Turrión Nieves¹, Ana Pérez Gómez¹, Ana Sánchez Atrio¹, Eduardo Cuende¹, Atusa Movasat¹, Fernando Albarrán Hernández¹, Henry Moruno¹, M José León¹, David Diaz², Jorge Monserrat² and Melchor Álvarez de Mon^1,2, ¹University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ²Laboratory of Immune System Diseases, Department of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain
Background/Purpose: Mechanisms regulating the chronic autoimmune response in rheumatoid arthritis (RA) are not well understood. However, activated T CD4+ play a pivotal role initiating and…
Abstract Number: 1398 • 2014 ACR/ARHP Annual Meeting
Spontaneous Regression of Methotrexate (MTX)-Related Lymphoproliferative Disorder Correlates with Lymphocyte Restoration after MTX Withdrawal
Shuntaro Saito¹, Yuko Kaneko¹, Katsuya Suzuki¹, Michihide Tokuhira² and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Hematology., Saitama Medical Center, Saitama Medical University., Saitama, Japan
2013 > Five patients were given chemotherapy after the diagnosis of MTX-LPD, so we analyzed the remaining 27 patients in this study. Baseline characteristics of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].